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The natural cytotoxicity receptor (NCR) family is constituted by NKp46, NKp44, and 
NKp30 in humans, which are expressed mainly on natural killer (NK) cells and are encoded 
by the ncr1, ncr2, and ncr3 genes, respectively. NCRs have classically been defined as 
activating receptors that trigger cytotoxicity and cytokine responses by NK cells upon 
engaging with ligands on tumor cells. Several new findings, however, have challenged 
this model and identified alternative mechanisms regulating the function of NCRs. 
Recent reports indicate that ligand matters, since the interaction of NKp44 with distinct 
ligands on target cells can either activate or inhibit NK cells. Also, the NCRs have been 
found to interact with distinct specificities to various heparan sulfate glycosaminogly-
cans, which are complex polysaccharides found in extracellular matrix or on cell surface 
heparan sulfate proteoglycans (HSPGs). The NCRs can engage with HSPGs in trans as 
a co-ligand on the target cells or in cis on the NK cell surface to regulate receptor–ligand 
interactions and NK cell activation. A number of splice variants of ncr2 and ncr3 have 
also been identified, and a predominant expression of certain variants results in inhib-
itory signaling through NKp44 and NKp30. Several recent studies have found that the 
selective expression of some of these inhibitory splice variants can significantly influence 
outcome in the contexts of cancer, infection, and pregnancy. These findings establish 
that NCR functions are more diverse than originally thought, and better understanding 
of their splice variant expression profiles and ligand interactions are needed to establish 
their functional regulation in the context of human health.
Keywords: natural cytotoxicity receptors, natural killer cells, RNA splice variants, cytotoxicity, cancer immunology, 
virus immunity, human immunology, pregnancy
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iNTRODUCTiON
It has become increasingly clear that human natural killer (NK) 
cells use an array of germline-encoded cell surface receptors 
to spontaneously recognize and respond to the abnormal sta-
tus of tumor cells, virus-infected cells, and stressed cells (1). 
Different NK cell surface receptors transduce either activating 
or inhibitory signals, directly or through associated adaptor 
proteins, to dynamically regulate the activation state of NK cells 
(2–4). Inhibitory receptors, such as killer cell Ig-like receptors 
(KIRs) and CD94/NKG2A, provide NK cells with a dominant, 
tolerizing immune checkpoint through their recognition of 
the MHC class I (MHC-I) molecules ubiquitously expressed 
on the surfaces of most normal cells. The loss of MHC-I by 
many transformed cells, however, overcomes this inhibitory 
checkpoint to favor activation. The loss of inhibitory restraint 
allows activating receptor signals to predominate and trig-
gers exocytosis of perforin and granzymes to induce targeted 
apoptosis of the MHC-I-deficient cell and localized secretion 
of pro-inflammatory cytokines [especially interferon (IFN)-γ, 
TNF-α, and several chemokines].
The activation signals transduced in NK cells are derived from 
adhesion molecules (especially LFA-1), co-stimulatory receptors 
(such as NKG2D, DNAM-1, and SLAM family receptors), and 
several activating receptors physically linked to the immu-
noreceptor tyrosine-based activation motif (ITAM)-containing 
transmembrane proteins, DAP12, TCR-ζ, and/or FcεRI-γ (2–4). 
The key ITAM-coupled activating receptors on human NK cells, 
include CD16 (FcγRIIIa), an activating subfamily of KIR (KIR2DS 
or KIR3DS receptors), CD94/NKG2C, and the natural cytotoxic-
ity receptors (NCRs).
The human NCRs consist of three receptors, named NKp46 
(NCR1, CD335), NKp44 (NCR2, CD336), and NKp30 (NCR3, 
CD337). These NCR were classically defined as germline-encoded 
receptors that play important roles in the activation of human 
NK cells toward transformed target cells (5, 6). Recent work, how-
ever, has established that the NCRs can also generate inhibitory 
responses under certain circumstances. Here, we will review our 
current understanding of the expression and function of NCRs 
on NK cells, particularly in humans, although it is important to 
note that the NCRs are also expressed on other innate lymphoid 
cells (ILCs) and a subset of T cells, which has been previously 
reviewed elsewhere (7, 8).
NCRs AND THeiR STRUCTUReS
The NCRs were initially discovered and characterized by the 
laboratories of Alessandro and Lorenzo Moretta in the late 
1990s (9–13). They are type I transmembrane glycoproteins that 
were originally recognized as activating receptors and named in 
accordance with their molecular weight on SDS-PAGE (NKp30, 
NKp44, and NKp46). NKp46 is the only NCR also expressed in 
mice, although a receptor analogous to NKp30 has been shown 
to be expressed in 1 of 13 mouse strains examined (14) and in 
rats (15, 16). While the ncr2 and ncr3 genes encoding NKp44 and 
NKp30, respectively, are localized to human MHC class III locus 
on chromosome 6, the NKp46 encoding gene, ncr1, is found 
near the leukocyte regulatory complex on human chromosome 
19 (10, 12, 13).
NKp46 has been shown to be a highly selective marker of all 
NK cells in mouse and man, although surface expression can be 
low on some NK  cells, particularly in humans, and the recep-
tor is also expressed on some ILCs and a small subset of T cells 
(9, 17, 18). Importantly, NKp46 is not expressed by CD1d-
restricted invariant NKT cells in mice and humans (17). NKp46 
has been shown to provide NK cells with the capacity to recognize 
and kill a variety of tumor target cells (19–21). NKp46 ligands have 
been reported to be enriched in areas of high malignant potential 
and high proliferation within melanoma lesions, whereas sur-
rounding normal melanocytes were found to lack NKp46 ligands 
(22). Evidence in mice also suggests that NKp46 also contributes 
to the development of type 1 diabetes by interacting with an 
uncharacterized ligand on pancreatic islet beta cells (21). As a 
tumor immunosuppressive mechanism, the surface expression 
of NKp46 on NK cells can be down-modulated by exposure to 
l-kynurenine, which is a tryptophan catabolism product gener-
ated by the indoleamine 2,3-dioxygenase (IDO) enzyme in tumor 
microenvironments (23).
NKp30, similar to NKp46, is expressed on nearly all human 
NK  cells (13). This NCR has been shown to play important 
roles in crosstalk between NK  cells and dendritic cells (DCs) 
through promoting both the maturation of and the cytotoxicity 
of immature DC (24, 25). Surface expression levels of NKp30 
and NKp46 can be upregulated by IFN-α, IL-2, and prolactin 
and downregulated by cortisol and methylprednisolone (26–28). 
In addition, both receptors are also commonly downregulated 
in “adaptive” or “memory-like” NK cells that are found in some 
cytomegalovirus-infected individuals (29, 30). TGF-β has been 
shown to selectively down-modulate the expression of NKp30, 
but not NKp46 on NK cells (31).
NKp44 is distinct among NCRs, since it is unique to humans 
and only expressed constitutively on some CD56bright NK  cells 
in a subset of individuals, but expression can be upregulated on 
essentially all NK cells after culture with IL-2, IL-15, or IL-1β (11, 
32). Similarly, NKp44 can be upregulated on plasmacytoid DCs 
upon culture with IL-3 (33). Therefore, NKp44 may also be con-
sidered a marker of cytokine-activated NK cells in humans. IL-2-
induced upregulation of NKp44 on NK cells can be inhibited by 
prostaglandin E2, which is readily produced by tumor-associated 
fibroblasts, especially when exposed to NK cells in culture (34). 
Similarly, prednisolone can suppress IL-2-mediated upregulation 
of NKp44 (26).
The extracellular domains of NCRs consist of one (NKp30 and 
NKp44) or two (NKp46) Ig-like domains that are responsible for 
ligand binding (10, 12, 13). Ligand binding and signaling function 
by NKp30 is highly dependent upon integrity of the membrane 
proximal stalk region (35). Crystal structures have revealed that 
NKp30 and NKp44 can form homodimeric structures with NKp30 
dimerizing in a head-to-tail fashion to form an I-type Ig-like fold 
and two NKp44 V-type Ig-like domains form a saddle-shaped 
dimer with unique disulfide bridging (36, 37). On the other 
hand, the crystal structure of NKp46 demonstrates two C2-type 
Ig-like domains that are folded and oriented similar to the Ig-like 
domains of KIRs (38). Evidence for a homodimerization interface 
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within the membrane proximal Ig-like domain of NKp46 has also 
been reported, and disruption of this dimerization interaction 
prevented ligand binding and activating function of the receptor 
(39). In conclusion, the three NCRs have unrelated structures, 
and grouping these receptors together is based more on their 
shared functional properties than related structure or genetic 
evolution (13).
The transmembrane domains of all three NCRs contain a 
positively charged lysine (NKp44) or arginine (NKp30 and 
NKp46) residue that interacts with acidic aspartic acid residues 
found in the transmembrane regions of the adaptor proteins 
DAP12 (NKp44) or TCR-ζ and/or FcεRI-γ (NKp30 and NKp46) 
(10). Physical association with DAP12 via these transmembrane 
charged residues is essential for surface expression of NKp44 
(40). The reductions in surface expression levels of NKp30 
and NKp46 on “adaptive” or “memory-like” NK cells is associ-
ated with the lack of FcεRI-γ expression in these cells (29, 30), 
exemplifying the importance of associating with this specific 
adaptor to transport a functional receptor to the cell surface. In 
addition to promoting surface expression, physical association 
with these associated transmembrane adaptors provides potent 
activation signaling function to the NCRs, since the tyrosine 
phosphorylation of their cytoplasmic ITAM domains results in 
the recruitment and activation of the Syk and ZAP-70 protein 
tyrosine kinases (2, 41). A unique activation signaling crosstalk 
has been reported between the NCRs, in which engagement of 
one NCR appears to initiate signaling through the others (41). 
Curiously, while several mRNA splice variants encoding NKp44 
have been described, the major protein product or isoform was 
found to also contain a cytoplasmic ITIM-like domain. Although 
early work suggested that this domain was incapable of providing 
inhibitory signaling function in an NK-like cell line (40), more 
recent work has demonstrated ITIM-mediated inhibitory func-
tion by NKp44 upon recognition of a specific ligand, proliferating 
cell nuclear antigen (PCNA), as detailed below (42).
LiGANDS OF THe NCRs
Despite a great deal of work by numerous research groups, our 
understanding of the ligands for NCRs is still not clearly estab-
lished. A diverse array of molecules have been report to interact 
with the extracellular domains of NCRs, including carbohydrate-
based contacts, cell surface proteins, and surprisingly, several 
intracellular-localized proteins that appear to reach the surface 
of infected or transformed cells. While engagement with most of 
these reported ligands stimulates activation of NK cells, some have 
been found to inhibit their functions. Our current understanding 
of putative ligands for NCRs and their functions are described 
below and summarized in Figure 1 and Table 1.
viral Ligands
Several viral-derived NCR ligands have been reported. Early 
work showed that the viral hemagglutinin (HA) of influenza virus 
on the surface of infected cells can readily engage with branched 
α-2,3- and α-2,6-sialylated O-glycan sequences conjugated 
on NKp46, and influenza-infected target cells can be killed by 
human NK cells in a NKp46-dependent manner (65–68). In fact, 
exposure of NK cells to influenza virions or free HA has been 
found to decrease NCR-mediated cytotoxicity, which was associ-
ated with loss of TCR-ζ protein expression (71). In addition, influ-
enza virus-infected DCs stimulate IFN-γ production by NK cells 
in an NKp46- and HA-dependent manner (69). Furthermore, it 
has been demonstrated that NKp46-deficient mice are more sus-
ceptible to death after infection with influenza virus (72). These 
interactions are consistent with the known sialic acid-binding 
properties of viral HAs. HAs from influenza and Sendai viruses 
have further been shown to also interact with NKp44, but not 
NKp30, and NKp44+ NK cells can kill cells infected with these 
viruses (54, 55). Similarly, both NKp46 and NKp44 were found to 
interact with the HA from avian Newcastle disease virus and this 
interaction potentiates cytotoxicity of target cells infected with 
this paramyxovirus (56).
Hemagglutinin from the orthopox family viruses, human 
vaccinia virus, and murine ectromelia virus has been shown to 
interact with NKp46 and NKp30 (43). Late-stage vaccinia virus-
infected target cells were further shown to be less susceptible to 
NK  cell cytotoxicity compared to uninfected targets, and this 
reduced killing was dependent upon viral HA in the target cells 
and NKp30 in the NK cells (43). The results from this study sug-
gest that the HA on the surface of vaccinia virus-infected cells 
interacts with NKp30 to either block its activating function or to 
mediate inhibitory signaling in NK cells, whereas NKp46 engage-
ment with vaccinia virus-derived HA on target cell surfaces 
stimulates cytotoxicity responses.
NKp44 has been shown to recognize the envelope glycopro-
teins from West Nile and Dengue flaviviruses (57). In particular, 
NKp44 was found to directly bind domain III of WNV envelope 
protein, but does not appear to involve viral HA, since independ-
ent of sialylation of oligosaccharides on NKp44. Consistent with 
this finding, West Nile virus-infected cells more readily bind a 
soluble recombinant form of NKp44 and stimulate NK cells to 
degranulate and produce IFN-γ in an NKp44-dependent manner 
(57). It should be noted that expression of Dengue viral non-
structural proteins in target cells reduces susceptibility to NK cell 
cytotoxicity through upregulating MHC-I expression (73).
In addition, NKp30 has been shown to directly interact with 
pp65, which is the main tegument protein of human cytomegalo-
virus (HCMV) (44). HCMV infected target cells were found to 
be less susceptible to NK cell-mediated killing, and this inhibi-
tion was lost if the target cells were infected with pp65-deficient 
HCMV or if anti-NKp30 blocking antibodies were added (44). 
The authors of this report further provided evidence that treating 
NK  cells with a recombinant soluble form of pp65 resulted in 
the dissociation of the TCR-ζ signaling adaptor protein from 
NKp30 (44). In this way, pp65 appears to provide HCMV with a 
mechanism to avoid NK cell-mediated immunity by disrupting 
activation signaling through NKp30.
Other Ligands expressed by Pathogens or 
Pathological Conditions
Natural cytotoxicity receptors have also been shown to directly 
recognize bacterial and parasite pathogens. It has been demon-
strated that NKp30 (and to a lesser extent, NKp46) can interact 
with the Duffy binding-like (DBL)-1α domain of Plasmodium 
FiGURe 1 | Ligands for natural cytotoxicity receptors (NCRs). Schematic representation of NCR ligands on tumor cell and their interaction with NKp30, 
NKp44, and NKp46 on natural killer (NK) cells. B7-H6 is an activating ligand for NKp30 upregulated on tumor cells and absent on normal cells. HLA-B-associated 
transcript 3 (BAT3)/Bcl2-associated anthogene 6 (BAG6) expressed in the nucleus moves to the plasma cell membrane or is released in exosomes. NKp44L is a 
splice variant isoform of the nuclear protein Mixed-lineage leukemia-5 protein that localizes to the tumor cell plasma membrane to serve as an activating ligand for 
NKp44. Proliferating cell nuclear antigen (PCNA) is a nuclear protein involved in DNA replication and repair mechanisms that relocalizes to the plasma membrane to 
serve as an NKp44 inhibitory ligand. Cytoskeleton type III filamentous vimentin is an intracellular protein but can be upregulated on the cell surface of infected cells, 
where it serves as a ligand for NKp46. Heparan sulfate proteoglycans (HSPGs) can interact with all NCRs. Heparan sulfate (HS) expressed on NK cell surface (cis 
interaction) can mask interactions with HSPG or other ligands on target cells (trans interactions).
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falciparum erythrocyte membrane protein-1 to mediate cytolysis 
of malaria-infected erythrocytes (45). The interaction appears 
to be direct, since the effect can be inhibited by the addition of 
recombinant soluble forms of these NCRs or peptides matching 
the sequence of DBL-1α (45).
It has been reported that Mycobacterium bovis bacillus 
Calmette-Guérin (BCG) can directly interact with NKp44, and 
exposure to BCG can increase NKp44 expression on CD56bright 
NK cells (58). This study also found that additional Mycobacterium 
family members can bind NKp44, such as Nocardia farcinica 
and Pseudomonas aeruginosa. Interactions of these bacteria 
with NKp44 did not activate NK cell functions, however, so the 
relevance of these interactions is currently unclear.
NKp44 has been reported to recognize an uncharacterized ligand 
on cartilage-derived chondrocytes, and cytotoxicity of primary 
chondrocytes by long-term IL-2 activated-NK cells was inhibited 
by an NKp44-blocking antibody (59). These results suggest that 
NKp44 activation signaling may promote NK cell-mediated auto-
immunity in chronic inflammatory cartilaginous disease.
Heparan Sulfates
Heparan sulfate (HS) glycosaminoglycans (GAGs) have also been 
shown to interact with all of the NCRs, with different affinities 
for the three receptors (46–48, 60). While these carbohydrate-
directed interactions likely do not represent primary ligands 
for the NCRs, they appear to have the capacity to regulate NCR 
function or may play a supporting role as co-ligands (61). HS 
GAGs consist of long, unbranched, anionic polysaccharides 
that are found on cell surfaces and the extracellular matrix (74). 
The HS GAG polysaccharides are composed of repeating disac-
charide units of uronic acid (iduronic or glucuronic acid) and 
glucosamine that are differentially sulfated at N, 2-O, 3-O, and 
6-O positions to generate highly diverse structures with unique 
protein binding properties (75). HS GAG can be conjugated to 
a small subset of proteins to form HS proteoglycans, including 
syndecans and glypicans, and their negative-charged configura-
tions can provide docking sites for basic domains on chemokines, 
FGF, and wnt ligand family members, thereby “presenting” them 
to cell surface receptors (76–79).
Interestingly, HS GAG are highly diverse structures, and the 
three NCRs preferentially recognize highly sulfated HS structures 
via basic amino acid patches on the receptor surfaces, and each 
NCR demonstrates distinct HS binding specificity (47, 48, 60). 
Therefore, it is conceivable that each NCR has the capacity 
to distinguish particular configurations of HS GAG primary 
and tertiary structures that might be uniquely expressed in the 
TAbLe 1 | Ligands for natural cytotoxicity receptors.
Receptor Ligands Function Reference
NKp30 Hemagglutinin (HA) of human vaccinia 
virus
Inhibition (43)
pp65, Main tegument protein of human 
cytomegalovirus
Inhibition (44)
(DBL)-1α domain of Plasmodium 
falciparum erythrocyte membrane 
protein-1
Activation (45)
Heparan sulfate (HS) glycosaminoglycans 
(GAGs)
Activation/
regulation
(46–48)
BAT3/BAG6 Activation (49–51)
B7-H6 Activation (52, 53)
NKp44 Redirected cytotoxicity and blockade of 
natural cytotoxicity with NKp44 antibody
Activation (11)
HA of influenza and Sendai viruses Activation (54, 55)
HA from avian Newcastle disease Activation (56)
Domain III of WNV envelope protein of 
West Nile and Dengue virus
Activation (57)
Mycobacterium bovis bacillus Calmette-
Guérin (BCG)
Unclear (58)
Unknown ligand on cartilage-derived 
chondrocytes
Activation (59)
HS GAGs Activation/
regulation
(47, 60, 61)
NKp44L Activation (62, 63)
Proliferating cell nuclear antigen Inhibition (42, 64)
NKp46 HA of influenza virus Activation (65–69)
HA of avian Newcastle disease Activation (56)
HA of human vaccinia virus Activation (43)
(DBL)-1α domain of Plasmodium 
falciparum erythrocyte membrane 
protein-1
Activation (45)
HS GAGs Activation/
regulation
(47)
Vimentin Activation (70)
5
Pazina et al. Regulation of NCRs
Frontiers in Immunology | www.frontiersin.org March 2017 | Volume 8 | Article 369
contexts of tumor microenvironments or sites of infection or 
inflammation. We have also shown the HS GAGs can interact with 
another NK cell receptor, KIR2DL4, and the binding can modu-
late receptor function (80). In addition, an interaction of NKp44 
with the heparan sulfate proteoglycans (HSPGs), syndecan-4, in 
cis on the NK cell surface can modulate the surface distribution 
and function of the receptor (61). Based on this and other reports 
(47), we have proposed that interactions with HSPGs in cis (on 
the surface of NK cells) may be impacting KIR2DL4 and NCR 
functions through masking interactions with HS GAG or other 
ligands on adjacent target cells (trans interactions) and/or may 
be affecting the trafficking of NCR to intracellular degradation 
and recycling pathways upon endocytosis (61, 81). In this way, cis 
interactions between NCR and HSPGs may provide an allosteric 
regulation mechanism. It is also intriguing to speculate that treat-
ment of patients with structurally related heparin as a therapeutic 
agent could impact NK cell functions through binding to NCRs 
and other NK cell surface receptors, including KIR2DL4.
intracellular Proteins As Cell Surface 
Ligands
The expression of a ligand for NKp44, named NKp44L, was first 
shown to be induced by the HIV-1 envelope protein gp41 on 
infected CD4+ T cells, and the expression increased in patients 
with increasing viral load (62). NKp44L is an activating ligand, 
since NK cell-mediated lysis of HIV-infected CD4+ T cells was 
inhibited by antibodies to NKp44 or NKp44L (62). The NKp44L 
was subsequently identified as a unique splice variant isoform of 
mixed-lineage leukemia-5 (MLL5) protein (63). While full-length 
MLL5 is a nuclear protein, the NKp44L splice variant is local-
ized near the plasma membrane in the cytoplasm and expressed 
in several tumor tissues and transformed cell lines, but not in 
normal tissues (63).
It was reported that NKp46 is involved in NK cell-mediated 
cytolytic attack of monocytes infected with Mycobacterium 
tuberculosis (20). Subsequent work established that this is due to 
an interaction with vimentin, which is expressed at high levels in 
infected monocytes and appears on the cell surface (70). Since 
vimentin is a type III intermediate filament of the cytoskeleton, 
however, it is unexpected to find on the cell surface, but this fol-
lows an emerging theme of several traditionally intracellular pro-
teins serving as putative cell surface ligands for NCRs. NK cells 
were more efficient at lysing target cells transfected to overexpress 
vimentin, and this cytotoxicity was inhibited by antibodies target-
ing NKp46 or vimentin (70).
In addition, NKp30 has been shown to interact with the HLA-
B-associated transcript 3 (BAT3)/Bcl2-associated anthogene 6 
(BAG6) protein to stimulate NK cytolytic responses (49). BAT3/
BAG6 is predominantly expressed in the nucleus, but can move 
to the plasma membrane in cells exposed to heat shock and can 
be secreted in exosomes by tumors and stressed cells (49, 82). 
BAT3/BAG6-expressing exosomes can stimulate cytokine release 
from NK cells upon interaction with NKp30, and BAT3/BAG6 
expression by DC is responsible for activation NK cells to mediate 
the crosstalk with DC (49, 50). Similarly, RIG-I stimulation of 
melanoma cell lines was shown to trigger the extracellular release 
of BAT3/BAG6-containing vesicles that can stimulate NK  cell 
cytolytic responses (51). In contrast, a soluble form of BAT3/
BAG6 has been found at high levels in the plasma of CLL patients 
and can suppress NK cytolytic responses, apparently by blocking 
recognition of this and other ligands on tumor cells (82, 83).
It was also reported that NKp44 can interact with PCNA, 
at target cell surfaces (42). PCNA is highly expressed in prolif-
erating cancer cells, where it is usually tightly associated with 
DNA and involved in DNA replication and repair mechanisms 
(84). Surprisingly, PCNA was found to migrate to the plasma 
membrane of target cells within the immunological synapse 
with NKp44-expressing NK cells, and this interaction inhibited 
cytolytic function and IFN-γ production by the NK cells (42). A 
second report has also described the interaction of PCNA and 
NKp44 and the association of PCNA with MHC-I molecules 
at the plasma membrane of tumor cells as a potential surface 
transport mechanism (64). The PCNA-induced inhibition was 
found to be mediated through the ITIM-like sequence in the 
cytoplasmic domain of NKp44 (42), despite earlier work in 
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which the ITIM-containing NKp44 cytoplasmic domain was 
shown to lack inhibitory function in the context of a chimeric 
receptor construct (40). It appears that PCNA interaction with 
the full NKp44 receptor establishes a unique conformation that 
transduces an inhibitory signal. Inhibitory function was also pre-
viously reported for NKp44 expressed on ILCs and plasmacytoid 
DCs (33, 85).
b7-H6
NKp30 has been found to bind to a cell surface protein member 
of the B7 family, named B7-H6 (52). B7-H6 is not normally 
expressed on healthy cells, but can be upregulated on human 
tumor cells through a Myc-mediated mechanism (86) or upon 
stimulation of monocytes and neutrophils with TLR ligands or 
pro-inflammatory cytokines (87). Upon recognition by NKp30, 
B7-H6 triggers cytotoxicity and cytokine production by NK cells 
(52). The interaction of B7-H6 with NKp30 is the most rigorously 
characterized of NCR ligands, since it is the only NCR–ligand 
interaction so far confirmed in an X-ray crystallography structure 
(53). It has also been shown that some tumors can escape NKp30 
recognition by shedding B7-H6 from their surfaces with the 
metalloproteases, ADAM-10, and ADAM-17 (88). Soluble and 
tumor-associated expression of B7-H6 in the peritoneum of ovar-
ian cancer patients has also been shown to correlate with reduced 
surface expression of NKp30 on peritoneal NK cells, presumably 
due to chronic interaction with ligand (89).
SPLiCe vARiANTS OF NCRs ReSULTiNG 
iN DiSTiNCT ReCePTOR iSOFORMS
A variety of mRNA splice variants encoding different isoforms 
of NCRs have been recognized for many years, but only recent 
work has established that some of these variant NCR isoforms 
can facilitate inhibitory functions. Distinct splice variant expres-
sion patterns have also been shown to correlate with outcomes 
in cancer and infectious disease, suggesting potential prognostic 
value in patients. A summary diagram of current reported func-
tions of distinct isoforms of NKp30 and NKp44 is presented in 
Figure 2.
Splice variants of ncr3
The expression of distinct isoforms of NKp30 is of great inter-
est, because this NCR is involved in DC-to-NK  cell crosstalk 
(25), can facilitate tumor cell recognition (13, 49, 90), and can 
influence the prognosis of different infectious diseases (91). Six 
splice variant transcripts have been identified from the ncr3 
gene, which was originally called 1C7 (92, 93). The most highly 
expressed ncr3 variants are designated a, b, and c that encode 
NKp30 proteins with an extracellular V-type Ig domain, while d, 
e, and f isoforms encode NKp30 receptors possessing a C2-type 
Ig domain that lacks 25 amino acids (93). The three members of 
each subgroup share three distinct cytoplasmic domains encoded 
by splice variations within exon 4. Although the d, e, and f protein 
isoforms of NKp30 have not been studied to date, several groups 
have examined the functions and interesting clinical outcomes 
associated with differential expression of the a, b, and c isoforms, 
as discussed below.
Alternative splicing of the ncr3 gene impacts functions of 
NKp30 isoforms that can be immunosuppressive or immu-
nostimulatory. Delahaye and colleagues expressed isoforms 
NKp30a, NKp30b, and NKp30c in the human NK cell line NKL 
to characterize their functions. It was shown that antibody- or 
B7-H6-mediated engagement of NKp30 on NKL transfected 
with either NKp30a or NKp30b isoforms stimulated produc-
tion of large amounts of IFN-γ, degranulation, and cytotoxicity 
responses. In contrast, engagement of NKp30c on NKL cell 
transfectants did not result in degranulation or elicit cytotoxicity, 
but instead produced the inhibitory cytokine IL-10 and very little 
IFN-γ (94). Similar immunostimulatory functions for NKp30a 
and NKp30b isoforms were observed when NKp30 transfectants 
were cocultured with DCs, whereas NKL-NKp30c transfectants 
demonstrated minimal responsiveness in these assays. In all of 
these experiments, NKp30a stimulated the most potent activating 
responses, whereas NKp30c was inhibitory or non-responsive, 
and NKp30b induced intermediate activation (94).
It was also shown that NKp30a associated more tightly 
with TCR-ζ upon crosslinking, as compared to NKp30c (94). 
Surprisingly, p38 MAP kinase activation was more pronounced 
when NKp30 was engaged in NKL-NKp30c cells then for NKL 
cells transfected with NKp30a or NKp30b. Furthermore, treat-
ment of NKL-NKp30c cells with a p38 inhibitor produced IFN-γ 
upon exposure to immature DCs (94). Therefore, NKp30b and 
especially NKp30a are stimulatory isoforms that can induce cyto-
toxicity and cytokine production, whereas NKp30c induces an 
immunosuppressive response that appears to involve activation 
of p38 and the production of IL-10.
NKp30 isoforms and Cancer
In addition to characterizing different functions for distinct 
NKp30 isoforms, Delahaye performed a retrospective analysis 
of NKp30 expression profiles in 80 patients with gastrointestinal 
stromal tumors (GIST), which is a malignancy that expresses 
NKp30 ligands. In that analysis, predominant expression of the 
immunosuppressive NKp30c isoform over the immunostimula-
tory NKp30a/b isoforms was found to be associated with reduced 
overall survival in imatinib-treated patients (94). Moreover, a 
subset of GIST patients with predominant expression of the 
NKp30c isoform and a distinct haplotype involving two SNPs in 
the ncr3 gene were found to be associated with particularly poor 
survival (94). For GI carcinomas and variety of other cancers, 
we observed that both cancerous and matched normal tissues 
manifested balanced NKp30c inhibitory and NKp30a/b activa-
tion profiles; yet, we found skewed NKp30 splice variant profiles 
in about 50% of a variety of tumor tissues compared to their 
matched normal tissues (95).
Neuroblastoma is another malignancy where NCRs are 
involved in the tumor cell recognition (96–98). Semeraro et al., 
found that neuroblastoma tumor samples express the NKp30 
ligand, B7-H6, and some patients with metastatic neuroblastoma 
had high levels of soluble B7-H6 in their serum, which was 
associated with reduced expression of NKp30 on the surface of 
NK  cells and higher degree of metastases (99). Furthermore, 
serum from patients with high soluble B7-H6 suppressed NK cell 
IFN-γ responses (99). Analysis of NKp30 isoform expression 
FiGURe 2 | Differential functions of different isoforms of NKp30 and NKp44. Immunostimulatory NKp30a and NKp30b isoforms interaction with ligands on 
tumor target cells or immature DCs (iDCs) to stimulate degranulation responses and interferon (IFN)-γ production. Inhibitory NKp30c isoform instead produces 
inhibitory cytokine IL-10 upon engagement. NKp30c is also less tightly associated with TCR-ζ and triggers stronger activation of p38 MAP kinase. The NKp44-1 
isoform contains a cytoplasmic ITIM that can transduce inhibitory signals when engaged with proliferating cell nuclear antigen (PCNA) ligand on target cell surface 
(pathway “A”), leading to decreased cytotoxicity and IFN-γ production. In contrast, all three NKp44 isoforms can engage with NKp44L to transduce activation 
signaling through DAP12 (pathway “B” for NKp44-1) that triggers cytotoxicity and IFN-γ production.
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suggested lower expression of NKp30a/b isoforms in patients with 
metastatic neuroblastoma compared to patients with localized 
disease or healthy donors. Comparison of the ratios of expres-
sion of mRNA for individual NKp30 isoforms revealed that high 
expression of the suppressive NKp30c isoform over the activating 
NKp30b isoform was associated with shorter progression-free 
survival of patients with metastatic disease (99). Surprisingly, 
IFN-γ was found to suppress the expression of B7-H6 and BAT3 
mRNA, whereas IL-10 increased B7-H6 mRNA expression on 
neuroblastoma tumors. The results of this study suggest that 
high expression of IL-10 by NKp30c-expressing NK cells induces 
B7-H6 expression on tumor, thereby potentiating further expres-
sion of this immunosuppressive cytokine.
The potential prognostic value of NKp30 isoforms was also 
recently investigated in melanoma patients (100). The overall 
mRNA expression levels of each of the NKp30 isoforms were 
found to be reduced compared to expression in healthy donors, 
but expression ratios between the isoforms did not differ. Levels 
of mRNA expression of the immunosuppressive NKp30c isoform 
were found to be higher on NK cells from stage IV melanoma 
patients, but relative expression levels of each NKp30 isoform did 
not predict overall survival of patients. Interestingly, long-term 
surviving melanoma patients were found to express higher levels 
of stimulatory NKp30a transcript. In accordance with this finding, 
the long-term survivors were more likely to have SNPs associated 
with reduced expression of suppressive NKp30c and increased 
expression of NKp30a. Furthermore, NK  cells from long-term 
surviving patients exhibited increased degranulation potential in 
response to NKp30 stimulation (100). Therefore, higher expres-
sion of NKp30a in melanoma patients appears to be beneficial.
NKp30 isoforms and infectious Diseases
Surface expression NKp30 on NK cells was found to be down-
regulated in HIV-1 patients, but expression patterns of NKp30 
isoforms do not affect disease progression or survival (101). 
NK  cells from hepatitis C virus (HCV)-infected patients also 
showed reduced expression of NKp30 on the surface of NK cells, 
and expression of the immunosuppressive NKp30c transcript 
was found to be significantly decreased in infected patients com-
pare to healthy controls (102). Also NKp30a/NKp30c ratio was 
significantly higher compared to healthy individuals suggesting 
an immunostimulatory profile in infected patients. If stratified 
according to mRNA expression levels, patients with low expres-
sion of all three isoforms had lower surface expression of NKp30 
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on NK cells, but higher ratio of NKp30a/NKp30c isoform tran-
scripts. Accordingly, NK cells from these patients exhibited more 
potent degranulation and cytokine production responses upon 
engagement of the receptor, as compared to healthy controls 
(102). Interestingly, positive correlations were observed between 
NKp30a isoform mRNA levels and liver stiffness and between 
NKp30a/NKp30c ratio and a measure of liver fibrosis, suggest-
ing that reduction of immunosuppressive NKp30c isoform and 
increase of immunostimulatory NKp30a isoform is associated 
with advanced liver disease in HCV-infected patients.
NKp30 in the Decidua of Pregnant women
Natural killer cells from decidual tissue in pregnant uterus (dNK) 
have unique phenotypical and functional properties compared 
to NK cells found in peripheral blood (pNK) (103). Mouse stud-
ies originally demonstrated that dNK cells function to support 
embryo implantation by secretion of numerous factors, including 
IFN-γ, to promote angiogenesis and trophoblast invasion (104). 
Comparison of freshly isolated pNK and dNK  cells from the 
same pregnant donors showed that pNK cells express high levels 
of NKp30a and NKp30b isoforms and low levels of NKp30c iso-
form, while dNK cells had high levels of NKp30c but significantly 
lower amounts of NKp30a/b (105). While crosslinking NKp30 
on IL-15-stimulated pNK  cells induced degranulation, freshly 
isolated dNK  cells did not degranulate, and co-crosslinking 
NKp30 in dNK cells did not inhibit NKp46-mediated degranula-
tion, consistent with the lack of activation by NKp30c in previ-
ously described studies by Delahaye et al. (94, 105). Coculturing 
pNK  cells in presence of IL-15 and IL-18 induced increased 
expression of NKp30a/b isoforms, whereas further addition 
of TGF-β suppressed the induction of expression of all three 
isoforms, although expression of NKp30b and NKp30c isoforms 
was greater than NKp30a upon addition of TGF-β (105). Overall, 
the combination of IL-15, IL-18, and TGF-β, which are found 
together in the decidual stromal microenvironment, shifted 
pNK cells toward higher expression of inhibitory NKp30c isoform 
and expression of other markers characteristic of dNK cells (105).
Shemesh et al. found significantly increased mRNA encoding 
the activating NKp30a/b isoforms in the placenta of women 
who had experienced sporadic or recurrent miscarriage within 
the first trimester, whereas this shift toward activating isoforms 
was not evident in the peripheral blood (106). The increase in 
activating isoforms did not correlate with higher expression of 
TNF-α, IFN-γ, IL-10, and placental growth factor mRNAs in 
the placental tissue of those women who experienced sporadic 
miscarriage, as compared to those that had undergone elective 
abortions. These results suggest that increased expression of these 
activating isoforms of NKp30 on dNK cells may be in some way 
contributing to failed pregnancies through promoting dysregu-
lated cytokine production in the placenta.
Splice variants of ncr2
Three major mRNA splice variants of ncr2 have been recognized, 
and one of these (NKp44-1) encodes the classic receptor that 
possesses a cytoplasmic ITIM, while the others (NKp44-2 and 
NKp44-3) have alternative sequences in the cytoplasmic region 
that lack ITIMs. It has long been known that IL-2-cultured 
NK  cells upregulate expression of an activating form of 
NKp44-1 associated with the transmembrane signaling protein, 
DAP12, which becomes tyrosine phosphorylated upon recep-
tor engagement with an antibody (11, 40, 41). Recent analysis 
of the major NKp44 isoforms, however, has demonstrated that 
isolated human NK cells cultured in IL-2- or IL-15 express pre-
dominantly NKp44-1 mRNA and have reduced capacity to kill 
PCNA-transfected target cells in an NKp44-dependent manner 
(12, 107). Furthermore, NK-92 cells transduced to overexpress 
NKp44-1 show suppressed cytotoxicity and diminished immune 
synapse formation toward PCNA-transfected target cells, as 
compared to NK-92 transduced to overexpress the other isotypes. 
These results indicate that the NKp44-1 isoform is an inhibitory 
receptor when engaged with the PCNA ligand expressed by 
target cells, whereas NKp44-2 and NKp44-3 do not transduce 
inhibitory signals (107).
NKp44 isoforms in Cancer
Shemesh et al. studied the impact of NKp44 isoforms on overall 
survival of patients with acute myeloid leukemia (AML) using 
TCGA RNA-Seq data (107). Whereas no survival advantage 
was found in newly diagnosed patients who expressed mRNA 
encoding NKp44, as compared to those lacking expression, 
survival was significantly diminished in patients who exclusively 
expressed NKp44-1, as compared to patients who also expressed 
at least some detectable level of NKp44-2 and/or NKp44-3 or 
lacked NKp44 expression altogether. These results imply that 
NKp44 plays a key role in NK  cell responsiveness toward 
AML tumors, but exclusive expression of the ITIM-containing 
NKp44-1 isoform can stifle these beneficial responses, presum-
ably through inhibitory signaling, thereby resulting in poor 
patient outcome.
The same group found higher incidence of NKp44 mRNA in 
various solid tumor tissues, as compared to surrounding normal 
tissues (95). Those tumor samples that expressed NKp44 mRNA 
were found to consist of predominantly NKp44-1 isoform. Thus, 
NK cells in the tumor microenvironment predominantly express 
the inhibitory NKp44 isoform.
NKp44 in the Decidua of Pregnant women
Siewiera et  al. found that while NKp44-2 mRNA is expressed 
more by freshly isolated pNK cells than NKp44-1 and NKp44-
3, dNK  cells from women undergoing elective first trimester 
abortions (healthy pregnancies) express all three isoforms of 
NKp44 at similar levels (105). While crosslinking NKp44 on 
IL-15-stimulated pNK cells induces degranulation, crosslinking 
on freshly isolated dNK  cells did not result in degranulation 
and co-crosslinking suppressed degranulation in response to 
crosslinking NKp46, demonstrating predominant inhibitory 
function for NKp44 in decidual/placental NK cells (105).
Shemesh et  al. also found that NKp44-2 and NKp44-3 
isoforms predominated in decidual tissue obtained from the 
majority of first trimester spontaneous abortions, while a NKp44-
1-dominant (inhibitory) profile was found in dNK  cells from 
most elective abortions or term deliveries (healthy pregnancies), 
which is consistent with the inhibitory function of dNK cells in 
the study by Siewiera et al. (95).
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Splice variants of ncr1
Recent work by Shemer-Avni et  al. has also provided new 
insights on differential splicing of ncr1 (108). Five major splice 
variants of ncr1 have been described, and three of these encode 
NKp46 protein isoforms containing both extracellular domains, 
while two lack the first Ig-like domain (D1, encoded by exon 
3). Surprisingly, NK-92 cells transduced with a D1-negative 
ncr1 cDNA degranulated significantly more efficiently toward 
HEK293T target cells, as compared to NK-92 cells transduced 
to express conventional NKp46 protein containing both Ig-like 
domains (108). Using NKp46-reactive antibodies, D1-negative 
NKp46 was not observed in fresh peripheral blood from healthy 
donors, but a subset expressing the NKp46 D1-negative receptor 
was found after long-time culturing of NK cells in IL-2 (108). This 
subset of NK cells containing D1-negative NKp46 degranulated 
more robustly in response to a combination of plate-bound anti-
NKp46 and anti-NKp30 antibodies (108).
This group also studied NKp46 isoform expression in upper 
airway lavage samples from pediatric patients with respiratory 
tract viral infections. While most of these samples expressed both 
NKp30 and NKp46 mRNA, none contained mRNA encoding 
NKp44. When ncr1 splice variants were analyzed, most of the lav-
age samples from virus-infected patients were found to contain 
D1-negative NKp46 isoform transcripts (108). Taken together, 
these results suggest that NK cells by IL-2 or viral infection can 
express isoforms of NKp46 lacking the D1 Ig-like domain, and 
NK  cells expressing these domain-deficient receptors exhibit 
increased functional capacity.
CONCLUSiON
Significant progress has been made in recent years to improve our 
understanding of the functions and ligand recognition capacities 
of NCRs. Clearly these receptors play important roles in NK cell 
recognition of tissue changes in cancer, viral infections, decidual 
tissues in pregnancy, and immature DC. This new knowledge 
is crucial for establishing the basis of molecular mechanisms 
controlling NK cell responses under these diverse conditions. In 
contrast to the original dogma that NCRs are exclusively acti-
vating receptors, several new findings have revealed inhibitory 
functions for these receptors.
Numerous ligands or co-ligands for NCRs have now been 
described. Several of these can surprisingly trigger inhibitory sig-
nals or induce production of inhibitory cytokines when engaged 
with NCRs. Furthermore, some of these putative ligands are classi-
cally nuclear or cytosolic proteins that appear to relocate to the cell 
surface in cancer cells, where they can engage with NCRs. Also, 
heparan sulfates seem to have capacity to interact with all three of 
the NCRs and may regulate their functions in trans and cis.
The study of differentially spliced isoforms of NCRs has 
revealed surprising insights, since some of these isoforms elicit 
inhibitory function. Furthermore, dominant expression of the 
inhibitory forms has been linked to poor outcome in the context 
of cancer, but healthy outcome in pregnancy. Nonetheless, our 
understanding of the complexities of NCR isoforms is still in its 
infancy and requires a great deal of additional study.
Future work is clearly needed to sort out true NCR ligands 
and functional mechanisms responsible for the functions of some 
NCR isoforms, and their complexities are growing. Importantly, 
a firmer foundation of understanding promises to provide 
potential opportunities as prognostic indicators of disease status 
or opportunities to develop therapeutic strategies to manipulate 
NCRs on NK cells that could be beneficial to treat a wide variety 
of human pathologies.
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